Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown
New York
10591
United States
Tel: 914-847-7000
Website: http://www.regeneron.com/
About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and over a dozen product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, and infectious and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through its unique VelociSuite® technologies and ambitious initiatives such as The Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world.
618 articles with Regeneron Pharmaceuticals, Inc.
-
Venture capitalists are flexing their muscles today with the significant support of pharma and biotech companies.
-
Gilmore O’Neill, formerly Biogen’s senior vice president, late-stage clinical development, jumped ship and will be Sarepta Therapeutics’ chief medical officer.
-
Regeneron and Zoetis Announce Collaboration to Research Antibody Therapies for Use in Animal Health
6/6/2018
Collaboration will also generate preclinical data to inform Regeneron's development of human medicines
-
New England Journal of Medicine Publishes Pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma
6/4/2018
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi announced that pivotal data from two trials evaluating cemiplimab in advanced cutaneous squamous cell carcinoma (CSCC) were published today in the New England Journal of Medicine (NEJM) and presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Regeneron's Investigational Ebola Treatment Shipping to Democratic Republic of the Congo for Use in Current Outbreak
5/31/2018
Regeneron Pharmaceuticals, Inc. announced that REGN-EB3 (also known as REGN3470-3471-3479), its investigational therapy that combines three fully-human monoclonal antibodies, is being shipped to the Democratic Republic of the Congo for use in the current Ebola virus infection outbreak.
-
Madrigal Pharmaceuticals announced positive topline data from its Phase II clinical trial of MGL-3196 in patients with biopsy-proven non-alcoholic steatohepatitis (NASH).
-
Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right.
-
New England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing DUPIXENT® (dupilumab) Improved Moderate-to-Severe Asthma
5/21/2018
Results showed DUPIXENT demonstrated a significant improvement in multiple asthma endpoints in two Phase 3 clinical trials.
-
Regeneron Announces Upcoming Investor Conference Presentation
5/18/2018
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its management presentation at the Goldman Sachs 39th Annual Global Healthcare Conference at 8:40 a.m. Pacific Time (11:40 a.m. Eastern Time) on Tuesday, June 12, 2018.
-
Regeneron Pharmaceuticals and its developmental partner Sanofi are eying the third quarter of this year to seek regulatory approval for Dupixent (dupilumab) as a potential monotherapy treatment for moderate-to-severe atopic dermatitis in adolescents.
-
Positive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis
5/16/2018
U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018
-
Training the next generation of scientists is a key for the future of the biotech industry and Regeneron Pharmaceuticals is taking a lead in that responsibility through its sponsorship of the Regeneron Science Talent Search.
-
Just about every week has plenty of exciting news in the biopharmaceutical industry, and this week was no different. Here’s a brief look back at some of our top stories.
-
Regeneron Reports First Quarter 2018 Financial and Operating Results
5/3/2018
Regeneron Pharmaceuticals, Inc. announced financial results for the first quarter of 2018 and provided a business update.
-
To ask the question, “What are the top biotech stocks?” is to get trapped in a maze of definitions: small cap versus large cap, upcoming catalysts, trending, or a byzantine series of technical evaluations. Rather than to attempt an overall view, here are a variety of biotech stocks that are worth...
-
Safety Concerns Force Regeneron to Halt High Doses of NGF-Inhibitor Fasinumab in Phase III Trial
5/3/2018
Regeneron has halted high dose treatment of a Phase III osteoarthritis drug following a risk-benefit assessment conducted by an Independent Data Monitoring Committee. -
Sanofi and Regeneron made a deal with pharmacy benefits manager Express Scripts for their Praluent, making it the exclusive PCSK9 inhibitor on their national formulary, essentially locking Amgen’s Repatha out of that market segment.
-
Sanofi and Regeneron to lower net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access for Express Scripts patients
5/1/2018
Sanofi and Regeneron Pharmaceuticals, Inc. announced they will lower the net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access from Express Scripts.
-
Regeneron and Sanofi to Lower Net Price of Praluent® (alirocumab) Injection in Exchange for Straightforward, More Affordable Patient Access for Express Scripts Patients
5/1/2018
Regeneron Pharmaceuticals, Inc. and Sanofi today announced they will lower the net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access from Express Scripts.
-
Regeneron and its longtime development partner Sanofi are keeping their proverbial fingers crossed that their profitable collaboration will yield yet another approved treatment this year.